

Ilze Bot

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2989867/ilze-bot-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

3,865
citations

36
h-index

60
g-index

104
ext. papers

4,454
ext. citations

7.4
avg, IF

5.09
L-index

#	Paper	IF	Citations
102	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.. <i>Cardiovascular Research</i> , 2022 ,	9.9	3
101	Inhibition of microRNA-494-3p activates Wnt signaling and reduces proinflammatory macrophage polarization in atherosclerosis. <i>Molecular Therapy - Nucleic Acids</i> , 2021 , 26, 1228-1239	10.7	2
100	Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 740531	5.4	1
99	Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells. <i>Cardiovascular Research</i> , 2021 , 117, 1309-1324	9.9	6
98	Mast Cell Distribution in Human Carotid Atherosclerotic Plaque Differs Significantly by Histological Segment. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021 , 62, 808-815	2.3	2
97	B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells. <i>Cardiovascular Research</i> , 2020 , 116, 295-305	9.9	7
96	Local Mast Cell Activation Promotes Neovascularization. <i>Cells</i> , 2020 , 9,	7.9	7
95	High LDL levels lessen bone destruction during antigen-induced arthritis by inhibiting osteoclast formation and function. <i>Bone</i> , 2020 , 130, 115140	4.7	1
94	Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics. <i>Circulation Research</i> , 2020 , 127, 1437-1455	15.7	96
93	Tc17 CD8+ T-cells accumulate in murine atherosclerotic lesions, but do not contribute to early atherosclerosis development. <i>Cardiovascular Research</i> , 2020 ,	9.9	2
92	Hypercholesterolemia Induces a Mast Cell-CD4 T Cell Interaction in Atherosclerosis. <i>Journal of Immunology</i> , 2019 , 202, 1531-1539	5.3	10
91	CD39 identifies a microenvironment-specific anti-inflammatory CD8 T-cell population in atherosclerotic lesions. <i>Atherosclerosis</i> , 2019 , 285, 71-78	3.1	11
90	Reply to: "The "cholesterol paradox" in patients with mastocytosis". <i>Atherosclerosis</i> , 2019 , 284, 262-263	3.1	
89	Flow Cytometry-Based Characterization of Mast Cells in Human Atherosclerosis. <i>Cells</i> , 2019 , 8,	7.9	14
88	Stress-induced mast cell activation contributes to atherosclerotic plaque destabilization. <i>Scientific Reports</i> , 2019 , 9, 2134	4.9	11
87	Mast Cells in Cardiovascular Disease: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
86	Antisense Oligonucleotide Inhibition of MicroRNA-494 Halts Atherosclerotic Plaque Progression and Promotes Plaque Stabilization. <i>Molecular Therapy - Nucleic Acids</i> , 2019 , 18, 638-649	10.7	10

85	Low human and murine Mcl-1 expression leads to a pro-apoptotic plaque phenotype enriched in giant-cells. <i>Scientific Reports</i> , 2019 , 9, 14547	4.9	2
84	Induction of HLA-A2 restricted CD8 T cell responses against ApoB100 peptides does not affect atherosclerosis in a humanized mouse model. <i>Scientific Reports</i> , 2019 , 9, 17391	4.9	3
83	CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. <i>Cardiovascular Research</i> , 2019 , 115, 729-738	9.9	29
82	Disruption of a CD1d-mediated interaction between mast cells and NKT cells aggravates atherosclerosis. <i>Atherosclerosis</i> , 2019 , 280, 132-139	3.1	3
81	Reply to "Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner". <i>Atherosclerosis</i> , 2018 , 278, 323-324	3.1	
80	Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. <i>Atherosclerosis</i> , 2018 , 268, 152-156	3.1	13
79	Defective Autophagy in T Cells Impairs the Development of Diet-Induced Hepatic Steatosis and Atherosclerosis. <i>Frontiers in Immunology</i> , 2018 , 9, 2937	8.4	12
78	Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner. <i>Atherosclerosis</i> , 2018 , 275, 214-224	3.1	11
77	Reply: The complexity of substance P-mediated mast cell activation. <i>Nature Reviews Cardiology</i> , 2017 , 14, 124	14.8	3
76	Stressed brain, stressed heart?. <i>Lancet, The</i> , 2017 , 389, 770-771	4.0	12
75	A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy. <i>Scientific Reports</i> , 2017 , 7, 52	4.9	37
74	Increased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency. <i>Circulation Research</i> , 2017 , 120, 78-84	15.7	40
73	Mast cells in atherosclerotic cardiovascular disease - Activators and actions. <i>European Journal of Pharmacology</i> , 2017 , 816, 37-46	5.3	34
72	Uremia does not affect neointima formation in mice. <i>Scientific Reports</i> , 2017 , 7, 6496	4.9	4
71	Leukocyte Bim deficiency does not impact atherogenesis in ldlr mice, despite a pronounced induction of autoimmune inflammation. <i>Scientific Reports</i> , 2017 , 7, 3086	4.9	3
70	Mast cells in rheumatic disease. <i>European Journal of Pharmacology</i> , 2016 , 778, 116-24	5.3	19
69	Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice. <i>Scientific Reports</i> , 2016 , 6, 37585	4.9	19
68	Quaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression. <i>Nature Communications</i> , 2016 , 7, 10846	17.4	66

67	Relaxing the artery: A new strategy to limit atherogenesis. <i>Atherosclerosis</i> , 2016 , 251, 510-511	3.1	
66	The impact of mast cells on cardiovascular diseases. <i>European Journal of Pharmacology</i> , 2016 , 778, 103-153	5.3	19
65	The origin of atherosclerotic plaque cells: Plasticity or not?. <i>Atherosclerosis</i> , 2016 , 251, 536-537	3.1	2
64	Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory response. <i>Scientific Reports</i> , 2016 , 6, 24248	4.9	15
63	Mast cells in human and experimental cardiometabolic diseases. <i>Nature Reviews Cardiology</i> , 2015 , 12, 643-58	14.8	76
62	Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 18-30	16.6	130
61	RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner. <i>Atherosclerosis</i> , 2015 , 238, 132-9	3.1	19
60	Mast cells as effectors in atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 265-71	9.4	80
59	Inhibition of MicroRNA-494 Reduces Carotid Artery Atherosclerotic Lesion Development and Increases Plaque Stability. <i>Annals of Surgery</i> , 2015 , 262, 841-7; discussion 847-8	7.8	31
58	The role of mast cells in atherosclerosis. <i>Hamostaseologie</i> , 2015 , 35, 113-20	1.9	4
57	Mast cells mediate neutrophil recruitment during atherosclerotic plaque progression. <i>Atherosclerosis</i> , 2015 , 241, 289-96	3.1	32
56	Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis. <i>Journal of Immunology</i> , 2015 , 194, 2208-18	5.3	15
55	Myocardin regulates vascular smooth muscle cell inflammatory activation and disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 817-28	9.4	71
54	Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. <i>British Journal of Pharmacology</i> , 2014 , 171, 723-34	8.6	67
53	CXCR4 blockade induces atherosclerosis by affecting neutrophil function. <i>Journal of Molecular and Cellular Cardiology</i> , 2014 , 74, 44-52	5.8	36
52	Akt2/LDLr double knockout mice display impaired glucose tolerance and develop more complex atherosclerotic plaques than LDLr knockout mice. <i>Cardiovascular Research</i> , 2014 , 101, 277-87	9.9	25
51	Complement factor C5a induces atherosclerotic plaque disruptions. <i>Journal of Cellular and Molecular Medicine</i> , 2014 , 18, 2020-30	5.6	29
50	Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. <i>Atherosclerosis</i> , 2014 , 235, 196-203	3.1	25

49	Circulating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis. <i>PLoS ONE</i> , 2014 , 9, e88984	3.7	11
48	Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis. <i>PLoS ONE</i> , 2014 , 9, e98289	3.7	5
47	Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display. <i>FASEB Journal</i> , 2013 , 27, 4136-46	0.9	6
46	Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. <i>European Heart Journal</i> , 2013 , 34, 3699-706	9.5	65
45	Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis. <i>Journal of Immunology</i> , 2013 , 191, 4573-80	5.3	42
44	An unexpected intriguing effect of Toll-like receptor regulator RP105 (CD180) on atherosclerosis formation with alterations on B-cell activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 2810-7	9.4	19
43	Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. <i>Cardiovascular Research</i> , 2013 , 97, 311-20	9.9	42
42	Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. <i>Journal of Lipid Research</i> , 2013 , 54, 1265-74	6.3	46
41	Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. <i>Circulation Research</i> , 2013 , 113, 1065-75	15.7	63
40	Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice. <i>FASEB Journal</i> , 2013 , 27, 265-76	0.9	15
39	T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 2558-65	9.4	30
38	Scavenger receptor-AI-targeted iron oxide nanoparticles for in vivo MRI detection of atherosclerotic lesions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 1812-9	9.4	52
37	Myocardin regulates vascular response to injury through miR-24/-29a and platelet-derived growth factor receptor- α . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, 2355-65	9.4	39
36	Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013 , 33, e75-83	9.4	44
35	Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient mice. <i>PLoS ONE</i> , 2013 , 8, e63360	3.7	19
34	Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development. <i>PLoS ONE</i> , 2013 , 8, e83134	3.7	9
33	Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 2311-20	5.6	27
32	Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro. <i>PLoS ONE</i> , 2012 , 7, e44694	3.7	25

31	Adenosine AB receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2197-205	9.4	20
30	Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 1960-9	9.4	39
29	Selective modulation of nuclear factor of activated T-cell function in restenosis by a potent bipartite peptide inhibitor. <i>Circulation Research</i> , 2012 , 110, 200-10	15.7	7
28	Interference of the CD30-CD30L pathway reduces atherosclerosis development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012 , 32, 2862-8	9.4	19
27	Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels. <i>Atherosclerosis</i> , 2011 , 214, 295-300	3.1	38
26	Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. <i>Atherosclerosis</i> , 2011 , 218, 53-60	3.1	75
25	Mast cells in atherosclerosis. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 820-6	7	52
24	Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE-/- mice. <i>Cardiovascular Research</i> , 2011 , 89, 244-52	9.9	52
23	Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. <i>Journal of Experimental Medicine</i> , 2011 , 208, 217-25	16.6	131
22	The neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. <i>Circulation Research</i> , 2010 , 106, 89-92	15.7	58
21	Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. <i>Circulation</i> , 2010 , 121, 2023-32	16.7	35
20	Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. <i>Atherosclerosis</i> , 2010 , 209, 74-80	3.1	66
19	Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. <i>Atherosclerosis</i> , 2010 , 211, 84-9	3.1	37
18	Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. <i>American Journal of Pathology</i> , 2010 , 176, 3073-84	5.8	52
17	Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis. <i>American Journal of Pathology</i> , 2010 , 177, 2753-64	5.8	49
16	Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 188-94	9.4	43
15	Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. <i>Journal of Vascular Surgery</i> , 2009 , 50, 152-60	3.5	34
14	Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. <i>Cardiovascular Research</i> , 2009 , 81, 278-85	9.9	27

13	The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2009 , 666, 132-56	3.6	27
12	Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. <i>Circulation Research</i> , 2008 , 102, 209-17	15.7	322
11	Mast cells: pivotal players in cardiovascular diseases. <i>Current Cardiology Reviews</i> , 2008 , 4, 170-8	2.4	19
10	Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. <i>Circulation</i> , 2007 , 115, 2516-25	16.7	214
9	Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. <i>Circulation</i> , 2007 , 116, 1812-20	16.7	78
8	Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. <i>Blood</i> , 2007 , 109, 122-9	2.2	69
7	Viral serine protease inhibitors as anti-atherosclerotic therapy. <i>Current Opinion in Investigational Drugs</i> , 2007 , 8, 729-35		2
6	Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1653-9	9.4	118
5	Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo. <i>Blood</i> , 2005 , 106, 1147-53	2.2	36
4	Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE ^{-/-} mice. <i>American Journal of Transplantation</i> , 2005 , 5, 1204-15	8.7	23
3	SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. <i>Circulation Research</i> , 2005 , 96, 784-91	15.7	314
2	Identification of an internalising peptide in differentiated Calu-3 cells by phage display technology; application to gene delivery to the airways. <i>Journal of Drug Targeting</i> , 2003 , 11, 383-90	5.4	7
1	Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE ^{-/-} mice. <i>Circulation Research</i> , 2003 , 93, 464-71	15.7	51